arrow
S

Swapna Verma

Institute of Mental Health
H指数:38
被引数:5,481

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Unraveling Suicidal Ideation and Behaviors in a Global Cohort of Individuals at Clinical High-Risk for Psychosis: Multivariable Correlates and Subthreshold Psychotic Symptoms

揭示全球临床高风险精神分裂症个体中的自杀意念与行为:多变量相关因素和阈下精神病症状

2026-09-130
OAAI
Processing Speed and Verbal Learning Ability as Predictors of Assessor-Rated and Ecological Momentary Assessment Self-Reported Functioning: Findings from AMP SCZ

处理速度和言语学习能力作为评估者评定和生态瞬时评估自报功能表现的预测因素:AMP SCZ的研究发现

2026-08-030
PRE
Synergising latent profile analysis and network analysis to elucidate the relationships among emotion dysregulation, post-traumatic stress disorder, dissociation, psychosis, and affective symptoms in individuals with trauma and severe mental illness

结合潜在剖面分析与网络分析以阐明创伤和严重精神疾病个体中情绪失调、创伤后应激障碍、解离、精神病性症状及情感症状之间的关系

2026-08-010
OAAI
Distinct correlates of post-traumatic stress disorder and subthreshold post-traumatic stress disorder considering a broad range of adverse experiences

创伤后应激障碍和阈下创伤后应激障碍在不同类型负面经历中的不同相关因素

2026-07-210
OAAI
Academic expectations stress; its associations with symptoms of depression and anxiety; and preliminary exploration of suicidality: results from a National Youth Mental Health Survey in Singapore

学业期望压力;其与抑郁和焦虑症状的关联;以及对自杀意念的初步探索:新加坡国家青少年心理健康调查的结果

2026-05-280
OAAI
Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiative

收集语言、语音声学和面部表情数据以预测精神分裂症及其他临床结果:AMP® SCZ倡议的策略

2025-10-150
OAAI
Association between non-adherence to fish oil or placebo as a risk factor of transition to psychosis in ultra-high-risk individuals in the NEURAPRO study

NEURAPRO研究中,鱼油或安慰剂不依从性与超高风险个体转为精神病风险因素之间的关联

2025-08-250
OA
The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures

加速药品合作计划®精神分裂症项目中的脑电图协议:测量指标的可靠性与稳定性

2025-06-060
OAAI
Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program

加速药物合作®精神分裂症计划中的数字健康技术

2025-06-030
OAAI
Gender-based analysis of body dissatisfaction among youths in Singapore: findings from the National Youth Mental Health Study

新加坡青少年身体不满意度的性别分析:来自国家青少年心理健康研究的发现

2025-04-250
OA
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample

加速药物伙伴关系中的认知评估®精神分裂症计划: 在不同的国际样本中协调优先事项和策略

2025-03-240
OAAI
Premorbid adjustment problems, negative symptoms, and cognitive impairment in a large international sample at clinical high risk for psychosis: Findings from the Accelerating Medicines Partnership—Schizophrenia

临床高风险精神病患者的大规模国际样本中,预后调整问题、阴性症状和认知障碍:来自加速药物合作计划—精神分裂症的研究结果

2025-01-010
OA
Development and temporal validation of a clinical prediction model of transition to psychosis in individuals at ultra-high risk in the UHR 1000+cohort

UHR 1000队列中超高危个体向精神病转变的临床预测模型的开发和时间验证

2024-09-160
OAAI
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis

加速药物伙伴关系®精神分裂症 (AMP®SCZ): 最大的全球精神病临床高风险前瞻性队列研究的基本原理和研究设计

2024-03-0712
OAAI